Tom Pickles

List of Publications by Year
in descending order

141 papers	5,199 citations	66234 42 h-index	95083 68 g-index
143 all docs	143 docs citations	143 times ranked	5613 citing authors

#	Article	IF	Citations
1	Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study. European Urology, 2013, 63, 597-603.	0.9	450
2	A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. European Urology, 2016, 70, 954-960.	0.9	290
3	Predictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive Patients. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1023-1032.	0.4	163
4	Shortâ€term outcomes of the prospective multicentre â€˜Prostate Cancer Research International: Active Surveillanceâ€™ study. BJU International, 2010, 105, 956-962.	1.3	157
5	Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification. European Urology, 2015, 67, 619-626.	0.9	129
6	Involved-Nodal Radiation Therapy As a Component of Combination Therapy for Limited-Stage Hodgkin's Lymphoma: A Question of Field Size. Journal of Clinical Oncology, 2008, 26, 5170-5174.	0.8	126
7	The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984â€“2000. Radiotherapy and Oncology, 2002, 65, 145-151.	0.3	118
8	Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. European Urology, 2015, 68, 814-821.	0.9	116
9	Pre-treatment risk stratification of prostate cancer patients: A critical review. Canadian Urological Association Journal, 2012, 6, 121-127.	0.3	115
10	Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU International, 2007, 100, 544-551.	1.3	107
11	Populationâ€based 10â€year oncologic outcomes after lowâ€doseâ€rate brachytherapy for lowâ€risk and intermediateâ€risk prostate cancer. Cancer, 2013, 119, 1537-1546.	2.0	99
12	Postoperative Radiotherapy for Stage pT3 Carcinoma of the Prostate: Improved Local Control. Journal of Urology, 1996, 155, 1983-1986.	0.2	97
13	The Impact of Explicit Values Clarification Exercises in a Patient Decision Aid Emerges After the Decision Is Actually Made. Medical Decision Making, 2012, 32, 616-626.	1.2	97
14	Longâ€term outcomes for patients with limited stage follicular lymphoma. Cancer, 2010, 116, 3797-3806.	2.0	94
15	Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational Study. European Urology, 2012, 62, 195-200.	0.9	89
16	The Self-Management of Uncertainty Among Men Undertaking Active Surveillance for Low-Risk Prostate Cancer. Qualitative Health Research, 2009, 19, 432-443.	1.0	88
17	Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer, 2002, 94, 362-367.	2.0	87
18	Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. International Journal of Radiation Oncology Biology Physics, 2003, 57, 11-18.	0.4	87

#	Article	IF	Citations
19	Underutilization of local salvage therapy after radiation therapy for prostate cancer11Funding: UBC Summer Student Research Program.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 701-706.	0.8	86
20	Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1355-1359.	0.4	83
21	Realâ€Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models. Biometrics, 2013, 69, 206-213.	0.8	81
22	Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. Journal of Clinical Oncology, 2012, 30, 1857-1863.	0.8	72
23	Rectal toxicity and rectal dosimetry in low-dose-rate 125I permanent prostate implants: A long-term study in 1006 patients. Brachytherapy, 2012, 11, 199-208.	0.2	66
24	Semantics in active surveillance for men with localized prostate cancer â€" results of a modified Delphi consensus procedure. Nature Reviews Urology, 2017, 14, 312-322.	1.9	65
25	Predictors of Unfavourable Repeat Biopsy Results in Men Participating in a Prospective Active Surveillance Program. European Urology, 2012, 61, 370-377.	0.9	64
26	The <scp>M</scp>elbourne Consensus Statement on the early detection of prostate cancer. BJU International, 2014, 113, 186-188.	1.3	64
27	Reduced Risk of Compressive Optic Neuropathy Using Orbital Radiotherapy in Patients With Active Thyroid Eye Disease. American Journal of Ophthalmology, 2014, 157, 1299-1305.	1.7	64
28	Impact of Providing Audiotapes of Primary Adjuvant Treatment Consultations to Women With Breast Cancer: A Multisite, Randomized, Controlled Trial. Journal of Clinical Oncology, 2003, 21, 4138-4144.	0.8	63
29	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	0.9	58
30	Brachytherapy Improves Biochemical Failureâ€"Free Survival in Low- and Intermediate-Risk Prostate Cancer Compared With Conventionally Fractionated External Beam Radiation Therapy: A Propensity Score Matched Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 91, 505-516.	0.4	57
31	Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2021, 137, 929-938.	0.6	57
32	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. Journal of Clinical Oncology, 2016, 34, 2493-2500.	0.8	56
33	Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival. International Journal of Radiation Oncology Biology Physics, 2014, 88, 87-93.	0.4	54
34	Incomplete testosterone suppression with luteinizing hormoneâ€releasing hormone agonists: does it happen and does it matter?. BJU International, 2012, 110, E500-7.	1.3	53
35	Late Urinary Side Effects 10ÂYears After Low-Dose-Rate Prostate Brachytherapy: Population-Based Results From a Multiphysician Practice Treating With a Standardized Protocol and Uniform Dosimetric Goals. International Journal of Radiation Oncology Biology Physics, 2014, 90, 570-578.	0.4	52
36	Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study. BJU International, 2016, 118, 366-371.	1.3	51

#	Article	IF	Citations
37	Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU International, 2007, 100, 315-319.	1.3	49
38	Urinary Symptom Flare in 712 125I Prostate Brachytherapy Patients: Long-Term Follow-Up. International Journal of Radiation Oncology Biology Physics, 2009, 75, 649-655.	0.4	49
39	Limitedâ€stage diffuse large Bâ€cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. Cancer, 2012, 118, 4156-4165.	2.0	49
40	Facilitating the implementation of empirically valid interventions in psychosocial oncology and supportive care. Supportive Care in Cancer, 2011, 19, 1097-1105.	1.0	47
41	Urinary incontinence in prostate cancer patients treated with external beam radiotherapy. Radiotherapy and Oncology, 2005, 74, 197-201.	0.3	46
42	Active surveillance for low-risk prostate cancer. Critical Reviews in Oncology/Hematology, 2013, 85, 295-302.	2.0	46
43	Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood, 2020, 136, 2803-2811.	0.6	46
44	Is prostate cancer screening costâ€effective? A microsimulation model of prostateâ€specific antigenâ€based screening for British Columbia, Canada. International Journal of Cancer, 2014, 135, 939-947.	2.3	39
45	The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada. Journal of Oncology, 2015, 2015, 1-7.	0.6	37
46	Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 35-41.	0.4	37
47	The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. Radiotherapy and Oncology, 2013, 109, 204-210.	0.3	34
48	Whole prostate D90 and V100: A doseâ€“response analysis of 2000 consecutive 125I monotherapy patients. Brachytherapy, 2014, 13, 32-41.	0.2	32
49	125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 40-50.	0.4	31
50	Incidence of Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 934-941.	0.4	31
51	Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. Radiotherapy and Oncology, 1996, 40, 245-247.	0.3	30
52	Pion conformal radiation of prostate cancer: results of a randomized study. International Journal of Radiation Oncology Biology Physics, 1999, 43, 47-55.	0.4	30
53	Using a surgical prostate-specific antigen threshold of >0.2Âng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial. Brachytherapy, 2018, 17, 837-844.	0.2	29
54	PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1040-1046.	0.4	28

#	Article	IF	Citations
55	Joint modelling of longitudinal and multiâ€state processes: application to clinical progressions in prostate cancer. Statistics in Medicine, 2016, 35, 3933-3948.	0.8	28
56	Development of indicators of the quality of radiotherapy for localized prostate cancer. Radiotherapy and Oncology, 2011, 99, 29-36.	0.3	26
57	Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program. Brachytherapy, 2013, 12, 343-355.	0.2	26
58	Impact of nicotinamide on human tumour hypoxic fraction measured using the comet assay. Radiotherapy and Oncology, 1997, 45, 175-182.	0.3	25
59	The treatment of choroidal melanoma with 198Au plaque brachytherapy. Radiotherapy and Oncology, 2001, 59, 153-156.	0.3	25
60	Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity. Brachytherapy, 2015, 14, 342-349.	0.2	25
61	The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia. Canadian Urological Association Journal, 2012, 6, 89-94.	0.3	24
62	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	2.6	24
63	Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Translational Andrology and Urology, 2018, 7, 98-105.	0.6	24
64	Decline in acute urinary toxicity: A long-term study in 2011 patients with prostate brachytherapy within a provincial institution. Brachytherapy, 2014, 13, 46-52.	0.2	21
65	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20â€year British Columbia Cancer Agency experience. British Journal of Haematology, 2017, 176, 234-240.	1.2	20
66	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 16.	0.3	20
67	Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation. Blood, 2015, 126, 579-579.	0.6	20
68	Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy. Cancer, 2008, 112, 1941-1948.	2.0	19
69	Canadian Prostate Brachytherapy in 2012. Canadian Urological Association Journal, 2013, 7, 51.	0.3	19
70	Outcomes of Proton Beam Radiotherapy for Large Non-Peripapillary Choroidal and Ciliary Body Melanoma at TRIUMF and the BC Cancer Agency. Ocular Oncology and Pathology, 2016, 2, 29-35.	0.5	19
71	Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy. Brachytherapy, 2015, 14, 334-341.	0.2	18
72	Patterns of Recurrence After Low-Dose-Rate Prostate Brachytherapy: A Population-Based Study of 2223 Consecutive Low- and Intermediate-Risk Patients. International Journal of Radiation Oncology Biology Physics, 2015, 91, 745-751.	0.4	18

#	Article	IF	Citations
73	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	0.9	18
74	Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). Blood, 2019, 134, 401-401.	0.6	18
75	Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting. Canadian Urological Association Journal, 2013, 2, 500.	0.3	17
76	Rectal Ulcers and Rectoprostatic Fistulas after ¹²⁵ I Low Dose Rate Prostate Brachytherapy. Journal of Urology, 2016, 195, 1811-1816.	0.2	17
77	Testosterone suppression in the treatment of recurrent or metastatic prostate cancer â€" A Canadian consensus statement. Canadian Urological Association Journal, 2017, 12, 30-7.	0.3	16
78	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. Haematologica, 2018, 103, e590-e593.	1.7	16
79	GU radiation oncologists consensus on bone loss from androgen deprivation. Canadian Journal of Urology, 2006, 13, 2962-6.	0.0	16
80	Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer. Brachytherapy, 2011, 10, 9-14.	0.2	15
81	Predictors of Androgen Deprivation Therapy Efficacy Combined With Prostatic Irradiation: The Central Role of Tumor Stage and Radiation Dose. International Journal of Radiation Oncology Biology Physics, 2011, 79, 724-731.	0.4	15
82	Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. Blood, 2020, 136, 1006-1010.	0.6	15
83	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	1.3	15
84	Population-Based Study of Cardiovascular Mortality Among Patients With Prostate Cancer Treated With Radical External Beam Radiation Therapy With and Without Adjuvant Androgen Deprivation Therapy at the British Columbia Cancer Agency. International Journal of Radiation Oncology Biology Physics, 2011, 80, 742-750.	0.4	14
85	A criterion-based audit of the technical quality of external beam radiotherapy for prostate cancer. Radiotherapy and Oncology, 2013, 107, 339-345.	0.3	13
86	Technology review: high-intensity focused ultrasound for prostate cancer. Canadian Journal of Urology, 2005, 12, 2593-7.	0.0	13
87	The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy. Brachytherapy, 2011, 10, 442-448.	0.2	12
88	The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 60-69.	2.3	12
89	Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk ofÂDeath. International Journal of Radiation Oncology Biology Physics, 2018, 100, 45-52.	0.4	12
90	Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma. Journal of Neuro-Oncology, 2002, 57, 215-220.	1.4	11

#	Article	IF	Citations
91	Population-based validation of a policy change to use long-term androgen deprivation therapy for cT3â€“4 prostate cancer: Impact of the EORTC22863 and RTOG 85-31 and 92-02 trials. Radiotherapy and Oncology, 2013, 107, 366-371.	0.3	11
92	Randomized study evaluating testosterone recovery using short-versuslong-acting luteinizing hormone releasing hormone agonists. Canadian Urological Association Journal, 2011, 5, 173-179.	0.3	11
93	In regard to Kupelian et al.: impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the psa era. IJROBP 2002;52:704â€“711. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1577-1579.	0.4	9
94	Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement. Canadian Urological Association Journal, 2013, 2, 95.	0.3	9
95	Secondary malignancy following radiotherapy for thyroid eye disease. Reports of Practical Oncology and Radiotherapy, 2016, 21, 156-161.	0.3	9
96	Highâ€“intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy. Brachytherapy, 2017, 16, 1101-1105.	0.2	9
97	FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP. Blood, 2010, 116, 854-854.	0.6	9
98	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	2.6	8
99	Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer. Cureus, 2015, 7, e276.	0.2	8
100	Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). World Journal of Urology, 2015, 33, 1735-1740.	1.2	7
101	A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate Cancer. Practical Radiation Oncology, 2019, 9, e274-e282.	1.1	7
102	Long-Term Results of PET-Guided Radiation Therapy in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma Treated with R-CHOP in British Columbia. Blood, 2017, 130, 823-823.	0.6	7
103	Pride or prejudice: Does Phoenix flatter radiation therapy?. Brachytherapy, 2014, 13, 299-303.	0.2	6
104	Efficacy of Palliative Radiation Therapy (RT) for Chemotherapy Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Population-Based Retrospective Review. Practical Radiation Oncology, 2021, 11, e203-e209.	1.1	6
105	What's a man to do? Treatment options for localized prostate cancer. Canadian Family Physician, 2004, 50, 65-72.	0.1	6
106	Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapy. Brachytherapy, 2015, 14, 350-358.	0.2	5
107	Using a Surgical PSA-Threshold (> 0.2 ng/mL) to Define Biochemical Failure in the ASCENDE-RT Phase 3 Trial. Brachytherapy, 2017, 16, S19.	0.2	5
108	The changing face of prostate cancer in British Columbia 1988-2000. Canadian Journal of Urology, 2002, 9, 1551-7.	0.0	5

#	Article	IF	Citations
109	Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. European Urology Open Science, 2022, 41, 126-133.	0.2	5
110	Complications of prostate cancer treatment. Lancet Oncology, The, 2014, 15, e151-e152.	5.1	4
111	Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. Canadian Urological Association Journal, 2020, 14, E588-E593.	0.3	4
112	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Advances, 2021, 5, 3647-3655.	2.5	4
113	Current status of PSA screening. Early detection of prostate cancer. Canadian Family Physician, 2004, 50, 57-63.	0.1	4
114	Prostate cancer and host metabolic factors. Lancet Oncology, The, 2008, 9, 1022-1023.	5.1	3
115	Use of combined androgen blockade for advanced prostate cancer in British Columbia. Journal of Oncology Pharmacy Practice, 2010, 16, 121-126.	0.5	3
116	Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. Canadian Urological Association Journal, 2013, 3, 460.	0.3	3
117	Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia. Canadian Urological Association Journal, 2015, 9, 409.	0.3	3
118	Re: Hermann et al., Low testosterone levels and Quality of Life. Radiotherapy and Oncology, 2006, 78, 107-108.	0.3	2
119	Prostate brachytherapy intraoperative dosimetry using a combination of radiographic seed localization with a C-arm and deformed ultrasound prostate contours. Brachytherapy, 2020, 19, 589-598.	0.2	2
120	Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials. Blood, 2010, 116, 417-417.	0.6	2
121	Biological Effectiveness of Fractionated Dose of Pions in Microscopic SCCVII Tumors: Comparison between Tumor Control Dose and Tumor Growth Time Assays. Japanese Journal of Cancer Research, 1995, 86, 600-606.	1.7	1
122	Prostate-specific antigen kinetics after failure of primary prostate cancer therapy: a valuable prognostic factor. Future Oncology, 2007, 3, 393-395.	1.1	1
123	Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy. Cancer, 2008, 112, 2322-2323.	2.0	1
124	Review of permanent interstitial 125I prostate brachytherapy patients treated with biochemical failure and a minimum of 4 years followup. Brachytherapy, 2008, 7, 116.	0.2	1
125	The Effect of Primary Gleason Pattern on Biochemical No Evidence of Disease (bNED) in Patients With Gleason 7, Localized Prostate Cancer Treated With 125I Brachytherapy. Brachytherapy, 2011, 10, S48-S49.	0.2	1
126	Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach. Blood, 2019, 134, 2845-2845.	0.6	1

#	Article	IF	Citations
127	The impact of surveillance imaging after curativeâ€intent radiotherapy for limitedâ€stage follicular lymphoma. British Journal of Haematology, 2021, 195, 802-805.	1.2	1
128	What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?. Canadian Journal of Urology, 2007, 14, 3621-7.	0.0	1
129	After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a population-based analysis. Brachytherapy, 2022, , .	0.2	1
130	Multiple Organ Toxicities in 1006 Prostate Brachytherapy Patients With Long-Term Followup. Brachytherapy, 2011, 10, S81-S82.	0.2	0
131	Aging Effect and Long-Term Erectile Function following I-125 Permanent Prostate Brachytherapy. Brachytherapy, 2014, 13, S16-S17.	0.2	0
132	34: Comparison of Existing Risk Stratification Tools for Localized Prostate Cancer. Radiotherapy and Oncology, 2016, 120, S13.	0.3	0
133	The impact of comorbidities on the benefits of prolonged androgen ablation in patients with T3-4 prostate cancer treated with external beam radiation therapy. Radiotherapy and Oncology, 2017, 124, 291-295.	0.3	0
134	External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. Canadian Urological Association Journal, 2017, 11, 94.	0.3	0
135	Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 62.	0.3	0
136	244 Long-Term Outcomes for Patients with Limited Stage Follicular Lymphoma: An Update of the BC Cancer Experience. Radiotherapy and Oncology, 2019, 139, S101-S102.	0.3	0
137	Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy. Canadian Urological Association Journal, 2021, 16, .	0.3	0
138	Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience. Blood, 2014, 124, 3076-3076.	0.6	0
139	Impact of Disease Extent and Distribution on Outcomes in Stage II Follicular Lymphoma Treated with Curative-Intent Radiation Therapy. Blood, 2021, 138, 2431-2431.	0.6	0
140	Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review. Leukemia and Lymphoma, 2022, , 1-4.	0.6	0
141	Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma. Leukemia and Lymphoma, 2022, 63, 2739-2742.	0.6	0